tbuckley/cabot-search huggingface dataset:
Gastrointestinal stromal tumor (GIST) presenting with acute pancreatitis
Authors: V. Senadhi, D. Arora, N. Jani
Journal: Endoscopy (2011)

A 58-year old woman presented with constant epigastric abdominal pain radiating to her back, of 1 week's duration. The patient had associated nausea, vomiting, anorexia, and weight loss. Physical examination revealed midepigastric tenderness without a palpable mass. Pertinent laboratory values included serum amylase of 410 units/L and lipase of 471 units/L.
Case 7-2015
Authors: Sebastian H. Unizony, Nancy D. Kim, Mai P. Hoang
Journal: New England Journal of Medicine (2015)

A 25-year-old man presented with oral ulcers and odynophagia. On examination, there were scattered pink papules and plaques on the trunk, thighs, and buttocks and multiple raised, erythematous nodules on both shins. A diagnostic procedure was performed.
Cerebral air embolism during endoscopic retrograde cholangiopancreatography: treatment with therapeutic hypothermia
Authors: Dilan Athauda, Garryck Tan, Eduardo De Pablo-Fernandez
Journal: Endoscopy (2014)

Cerebral air embolism (CAE) during endoscopic retrograde cholangiopancreatography (ERCP) is an uncommon complication, but of the nine previously reported cases, seven had fatal outcomes and one was left with severe hemiparesis [1] [2] [3].
Alternatives to statins in intolerant patients do lower cholesterol, study finds
Authors: Ingrid Torjesen
Journal: BMJ (2016)

Statins do cause painful muscle cramps in some patients, and alternative drugs can reduce low density lipoprotein cholesterol (LDL-C) levels, a two stage randomised clinical trial published online in JAMA has shown.1

Some patients taking statins report muscle pain or weakness when treatment is initiated or dosage increases, as well as relief when the drug is discontinued or dosage reduced. As a result, some at high risk of major cardiovascular events due to high cholesterol levels may be treated with low dose or intermittent statins or, alternatively, the cholesterol absorption inhibitor ezetimibe—but these strategies seldom achieve the cholesterol reductions recommended by current guidelines.

However, the results of a trial funded by Amgen, which markets proprotein convertase subtilisin/kexin type 9 (PCSK9), showed that evolocumab was more effective than ezetimibe at lowering LDL-C in statin intolerant patients.

The study involved 511 adult …
Odd Strategies for Keeping Cancer at Bay
Authors: N. Volkers, S. Jenks
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Odd Strategies for Keeping Cancer at Bay Get access Nancy Volkers, Nancy Volkers Search for other works by this author on: Oxford Academic PubMed Google Scholar Susan Jenks Susan Jenks Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 7, 5 April 1995, Pages 483–485, https://doi.org/10.1093/jnci/87.7.483 Published: 05 April 1995
966 PRIMARY BILIARY CIRRHOSIS IN LOMBARDIA, ITALY: A LOWER THAN EXPECTED FEMALE-TO-MALE INCIDENCE RATIO WITH HIGHER MORTALITY IN MEN
Authors: L. Moroni, P. Jepsen, P.M. Battezzati, E. Morenghi, A. Lleo, M. Podda, P. Invernizzi
Journal: Journal of Hepatology (2012)
1149 REDUCTION OF mir-122 EXPRESSION IN IL28B CT/TT CHRONIC HEPATITIS C PATIENTS WHO FAILED TO PEGYLATED-INTERFERON PLUS RIBAVIRIN TREATMENT
Authors: E. Estrabaud, M. Lapalus, P. Broet, S. De Muynck, O. Lada, K. Appourchaux, M. Martinot-Peignoux, I. Bieche, D. Valla, P. Bedossa, P. Marcellin, M. Vidaud, T. Asselah
Journal: Journal of Hepatology (2013)
Abstract 2463: Discovery of imidazo[1,5-<i>a</i>]pyrazine derived potent, selective and orally bioavailable ACK1 inhibitors.
Authors: Meizhong Jin, Jing Wang, Andrew Kleinberg, Mridula Kadalbajoo, Kam W. Siu, Andrew Cooke, Mark Bittner, Yan Yao, April Thelemann, Qunsheng Ji, Shripad Bhagwat, Kristen M. Mulvihill, Josef A. Rechka, Jonathan A. Pachter, Andrew P. Crew, David Epstein, Mark J. Mulvihill
Journal: Cancer Research (2013)

Abstract Activated Cdc42-associated kinase (ACK1) is a non-receptor tyrosine kinase originally identified by virtue of its binding to GTP-bound small GTPase Cdc42. Considerable attention has been paid to ACK1’s involvement in cancer in recent years. For example, gene amplification and over-expression of ACK1 were found in multiple cancers including lung, ovarian and prostate cancers and were associated with poor prognosis and metastatic phenotypes. Activated ACK1 has been shown to phosphorylate and activate androgen receptor function and to promote the progression of prostate cancer. More recently, activated ACK1 was found to phosphorylate and promote the activation of Akt, a protein kinase that plays a central role in growth, proliferation and cell survival in various cancers. Taken together, these literature data suggest that ACK1 is a potential target for cancer treatment. Several series of ACK1 inhibitors have been previously disclosed in literature. Unfortunately, compounds from these series suffer from poor oral pharmacokinetic (PK) properties which have prevented them from being utilized further for in vivo studies. Therefore, there is a clear need for potent, selective and orally bioavailable small molecule ACK1 inhibitors to further probe its role in cancer, both in the in vitro and in vivo setting. This report describes the medicinal chemistry effort towards a series of novel imidazo[1,5-a]pyrazine derived inhibitors of ACK1. Virtual screening led to the discovery of the initial hit, and subsequent exploration of structure-activity relationships and optimization of drug metabolism and pharmacokinetic properties led to the identification of potent, selective and orally bioavailable ACK1 inhibitors. Citation Format: Meizhong Jin, Jing Wang, Andrew Kleinberg, Mridula Kadalbajoo, Kam W. Siu, Andrew Cooke, Mark Bittner, Yan Yao, April Thelemann, Qunsheng Ji, Shripad Bhagwat, Kristen M. Mulvihill, Josef A. Rechka, Jonathan A. Pachter, Andrew P. Crew, David Epstein, Mark J. Mulvihill. Discovery of imidazo[1,5-a]pyrazine derived potent, selective and orally bioavailable ACK1 inhibitors. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2463. doi:10.1158/1538-7445.AM2013-2463
BI-32 * RISK FACTOR ANALYSIS FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WHO DID NOT RECEIVE SALVAGE THERAPY
Authors: W. Wick, B. Hentschel, D. Gramatzki, M. Simon, G. Schackert, J.-C. Tonn, M. Westphal, M. Tatagiba, M. Sabel, A. Weyerbrock, T. Pietsch, G. Reifenberger, M. Loeffler, M. Weller
Journal: Neuro-Oncology (2014)

BACKGROUND: A relevant fraction of patients does not receive salvage therapy at recurrence of glioblastoma initially treated according to current standards of care. Primary treatment may be of higher relevance in this patient group. Risk factors to prospectively determine which patients have a higher probability to receive salvage therapy have not been prospectively studied. METHODS: Patients (n = 1004) with first recurrence of a glioblastoma received no salvage treatment (n = 374; 37.3%, group N) or ≥1 line of postprogression therapy consisting of surgical resection +/- second radio- and/or chemotherapy (n = 630; 62.7%, group Y) in the prospectively assembled cohort of the German Glioma Network. Age, gender, Karnofsky Performance Status (KPS), extent of resection, O6-methylguanine methyltransferase (MGMT) and isocitrate dehydrogenase (IDH) 1/2 status as well as first line therapy were assessed as risk factors not to receive salvage therapy. RESULTS: Median overall survival in the whole cohort was 14.2 (95% confidence interval 13.4-15.0) months. It was 8.7 (95% CI 8.1-9.2) months in group N as opposed to 18.5 (95% CI 17.2-19.8) months in group Y patients. Positive prognostic factors to receive salvage treatment were age ≤ 60 years (odds ratio (OR), 2.9, p < 0.001), complete resection at first-line treatment (OR 1.8, p = 0.011) and KPS >70 (OR 1.7, p = 0.035), but not initial treatment with radiochemotherapy (versus radio- or chemotherapy) (OR 1.6, p = 0.051), gender (OR 1.1, p = 0.718), or MGMT (OR 1.5, p = 0.087). A multivariate analysis with test and validation set will be presented. CONCLUSION: In this analysis, the administration of salvage treatment expectedly was associated with prolonged survival. Older patients with incomplete resections or biopsies with lower KPS may particularly benefit from improved first-line treatment since these patients are less likely to receive salvage therapy. A concept of the EORTC and NOA proposes to assess the addition of bevacizumab to such patients with tumors lacking MGMT promoter methylation.
Endoscopic submucosal dissection for gastric tumors in various types of remnant stomach
Authors: Toshiyasu Ojima, Katsunari Takifuji, Masaki Nakamura, Mikihito Nakamori, Masahiro Katsuda, Takeshi Iida, Keiji Hayata, Makoto Iwahashi, Hiroki Yamaue
Journal: Endoscopy (2014)

<b>Background and study aims:</b> The aim of this study was to examine the clinical outcomes of endoscopic submucosal dissection (ESD) for gastric tumors in various types of remnant stomach. <b>Patients and methods:</b> Between January 2002 and March 2013, ESD was performed for 750 gastric tumors. Of these lesions, 49 were in a remnant stomach, and were included in the study. <b>Results: </b>The en bloc resection rate was 100 %. The curative resection rate was 82 %. The rate of perforation was high in patients with gastric conduits (28.6 %). Perforation was significantly more common in patients with lesions located on the suture line (4.9 % vs. 50.0 %; <i>P</i> = 0.0043). <b>Conclusion: </b>ESD for gastric tumors in the remnant stomach can be considered feasible and safe in clinical practice. However, the procedure is technically more difficult in patients with a gastric conduit, due to the increased risk of perforation at the suture line.
Abstract 2978: Nucleotide excision repair contributes to hexavalent chromium-induced double strand breaks and chromosomal damage
Authors: Laura C. Savery, Travis J. O'Brien, Amie L. Holmes, John P. Wise, Steven R. Patierno
Journal: Cancer Research (2010)

Abstract Certain hexavalent chromium (Cr(VI)) compounds are known human lung carcinogens. Cr(VI) causes several types of DNA damage including bulky adducts and crosslinks. Cr(VI)-induced tumors exhibit chromosomal instability (CIN), however, very little is known about mechanisms of these effects and the role that DNA repair plays in this process. Nucleotide excision repair (NER) is known to be involved in the repair of bulky DNA damage. Unrepaired or misrepaired lesions can lead to chromosomal aberrations (CAs). We investigated the role of NER leading to CAs using Chinese hamster ovary (CHO) parental (AA8) and NER-deficient cells (UV-5). We found that UV-5 cells displayed attenuated Cr(VI)-induced chromosome damage. In general, DNA lesions need to be converted to DNA double strand breaks (DSBs) in order to give rise to CAs. Therefore, we used the neutral Comet assay to measure the induction and repair of DSBs after Cr(VI)-induced damage. We found that both parental and NER-deficient cell lines displayed low levels of DSBs immediately after Cr(VI) treatment. Interestingly, DSB formation peaked after a 24h recovery period, and NER-deficient cells exhibited lower overall levels of DSBs than repair-proficient cells. All damage in both cell lines was repaired by 48h following Cr(VI) exposure. Taken together, our results suggest that Cr(VI)-induced DSBs are not directly formed by Cr(VI) exposure. Instead, these lesions develop as a consequence of repair of, or replication past, Cr(VI)-induced lesions. Importantly, our data suggests that NER contributes to Cr(VI)-induced genomic instability. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2978.
BICUSPID AORTIC VALVE: GENDER DIFFERENCE IN PREVALENCE, VALVE MORPHOLOGY AND BICUSPID AORTOPATHY
Authors: William K.F. Kong, Madelien Regeer, Kian Keong Poh, James Yip, Arnold Ng, Louise McCormack, Miriam Shanks, Vasileios Kamperidis, Nina Ajmone Marsan, Victoria Delgado, Jeroen Bax
Journal: Journal of the American College of Cardiology (2016)
UTILIDAD DE LA ULTRASONOGRAFÍA ENDOSCÓPICA EN LAS ESTENOSIS BILIARES DE ORIGEN INCIERTO
Authors: B Merino Rodríguez, O Nogales Rincón, A Fernández, A Ochoa, L Pérez Carazo, J Miranda, P Menchén Fernández-Pacheco, C González Asanza
Journal: Endoscopy (2011)

Introducción: Determinar la etiología de las estenosis biliares distales es particularmente complejo siendo crucial para realizar un apropiado manejo de las mismas.
PARE0022 First National Osteoarthritis Patients Survey in France: Patients Insights First!
Authors: L. Grange, F. Rannou, F. Berembaum, P. Richette, F. Beroud, A. Chaussier-Delboy, X. Chevalier, C. Dreux, P.A. Joseph, C. Roques, A. Sautet, F. Srour, J. Giraud, D.R. Bertholon, F. Nock, H. Servy, J.N. Dachicourt
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The (French) National osteoarthritis Alliance was created in 2011 to otpimise osteoarthritis patient care. <h3>Objectives</h3> One of its first initiative was the launch of a national patient survey in December 2012 to assess the main impacts and consequences of osteoarthritis in daily life. In addition to gathering patient needs, the results are expected to be able to sensibilise health authorities, and the public, about osteoarthritis patient9s realities. Whilst a true public health issue, osteoarthritis is nonetheless not a priority in prevention or support in national or local health decisions. <h3>Methods</h3> A self administered questionnaire was developed by experts of the National osteoarthritis Alliance. The questionnaire addressed previously unexplored issues. The survey consisted of 113 questions and was tested and validated by patients before being put on line at www.stop-arthrose.org. <h3>Results</h3> More than 70% of the 2,914 respondents were aged between 50 and 69 y old. Contrary to common perception, more than a third of them suffered with the first signs of osteoarthritis before the age of 40. Amongst the osteoarthritis worsening factors, overweight and obesity were present for 52,5% of the respondents, having a professional activity which impacts joints (49,7%) or previous joint trauma (31,8%). The more affected joints were (decreasingly ordered) the knees, the hands, the hips and the feet. Respondents describe a negative impact of osteoarthritis on many life aspects, notably mood (81,7%), leisure activities (77,2%), professional activity (70,8%), walking (66,5%), self image (63,5%) and family life (59,4%). The results are also compiled in a brochure “osteoarthritis: experiences and needs of affected people” which is available on the Internet site www.stop-arthrose.org <h3>Conclusions</h3> One of the first limits of this survey is its distribution, which was only available for proactive, information seeking internet users. Nonetheless, the results assist in better understanding patient experience, needs and profiles, This innovative survey is a first important step to better recognise osteoarthritis as experienced by patients. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4109
Obesity, insulin resistance and oxidative stress: implication for breast carcinogenesis.
Authors: CM Lewis, D Bu, DM Euhus
Journal: Cancer Research (2009)

Abstract Abstract #6025 Background: Obesity is associated with a modest increase in the risk of postmenopausal breast cancer (RR = 1.5 – 2.0); but, because nearly a third of the U.S. population is obese, the population attributable risk is estimated at 15%. Obesity can cause insulin resistance culminating in Type II diabetes. Notably, breast cancer incidence is significantly increased in the years preceding a diagnosis of type II diabetes. Because IGFBP-1 expression is tightly regulated by insulin, it is an excellent marker of insulin resistance in healthy individuals.&amp;#x2028; Methods: These data are based on well-annotated prospectively acquired baseline blood and breast tissue samples from 72 high risk women between the ages of 37 and 86 years who participated in a chemoprevention trial. None of the women had been diagnosed with Type II diabetes. Women with plasma IGFBP1 levels in the lowest tertile (mean 2.1 ng/ml) were classified as insulin-resistant.&amp;#x2028; Results: Plasma IGFBP1 was strongly inversely correlated with BMI (R2 = 0.247, P &amp;lt; 0.0001). Insulin-resistant women had marginally higher mean plasma free estradiol levels than women not classified as insulin-resistant (2.13 x 10-12M versus 1.53 x 10-12M, P = 0.072). There was no difference in plasma IGF1, IGF2, or IGFBP3 levels. Illumina whole genome expression microarray data was available for breast tissue from 55 women. Women classified as insulin-resistant showed evidence of an adaptive response to oxidative stress based on significant upregulation of NQO1, GSTK1, CYP4ZP2, and SRXN1 (P &amp;lt; 0.001).&amp;#x2028; Conclusions: Marginally increased circulating estradiol may contribute to the increased breast cancer risk observed in insulin-resistant women. However, insulin resistance increases oxidative stress in breast tissue and may promote carcinogenesis through induction of oxidative DNA damage. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6025.
FRI0444 Comparison of ACR (1990) and Eular/Printo/Pres (2010) Classification Criteria in Adult IGA Vasculitis: Table 1.
Authors: A. Hočevar, Ž. Rotar, V. Jurčić, A. Vizjak, M. Tomšič
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> In 2010 EULAR/PRINTO/PRES proposed new classification criteria for IgA vasculitis (IgAV).(1) In paediatric patient population these criteria have a higher diagnostic sensitivity than the older American College of Rheumatology (ACR) criteria.(1, 2) The performance of the new criteria has thus far not been evaluated in adult IgAV patients. <h3>Objectives</h3> To compare the performance of the ACR and EULAR/PRINTO/PRES classification criteria in adult IgAV. <h3>Methods</h3> Adult IgAV cases diagnosed using EULAR/PRINTO/PRES classification criteria at a tertiary rheumatology referral centre were critically reviewed in partially retrospective and partially prospective manner to assess whether these patients also fulfilled the ACR criteria. <h3>Results</h3> Between January 1, 2010 and December 31, 2013 96 new adult IgAV cases (median age 63.4; interquartile range 40.8–77.3 years; 60.4% males; male to female ratio 1.53) were identified according to EULAR/PRINTO/PRES classification criteria. Purpura was present in all patients (generalized in 33/96 (34.3%), necrotic 43/96 (44.8%), bullous 9/96 (9.4%)) and was the only manifestation in 19 (19.8%) cases. Joints were involved (arthralgia or arthritis) in 44/96 (45.8%), gastrointestinal tract in 35/96 (36.4%), and kidneys in 56/96 (58.3%) cases. Lung, heart and testicular involvement was rare - one case of each. In 96/96 cases IgA deposits in vessel walls was documented on direct immunofluorescence staining. 91/96 of cases fulfilled both EULAR/PRINTO/PRES IgAV and ACR classification criteria. However, 5/96 patients (5.2%) fulfilled the EULAR/PRINTO/PRES classification criteria only. The characteristics of these patients are shown in Table 1. <h3>Conclusions</h3> In an adult population the EULAR/PRINTO/PRES IgAV classification criteria have a higher sensitivity than the previously proposed ACR criteria, analogously to the findings in paediatric population. <h3>References</h3> Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010;69:798-806. Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum 1990;33:1114–21. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1906
AB0703 Temporomandibular joint involvement in children with juvenile idiopathic arthritis
Authors: Z. Dāvidsone, R. Šantere, Z. Krišjāne, I. Urtāne, V. Staņēviča
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Juvenile idiopathic arthritis (JIA) is the most common autoimmune heterogenic diseases group of unknown etiology with7 subtypes. There are markedly high prevalence of temporomandibular joint (TMJ) involvement- 17 - 87% depending on population and examination method (1). Contrast enhanced magnetic resonance imaging (MRI) is considered the optimal method for TMJ evaluation. Beside systemic therapy intraarticular (i/a) steroid injections and night splints are used in a cases of TMJ arthritis (2). <h3>Objectives</h3> To evaluate radiologic findings with contrast enhanced MRI in children with JIA and local terapy methods applied in a cases of TMJ arthritis. <h3>Methods</h3> Retrospectively 65 JIA cases with TMJ involvement were included analysing Children`s university hospital and Stomatology institute patient`s data. TMJ was examined with contrast enhanced MRI from 2010.-2012. Statystical analysis was performed with MS Excel 2007, SPSS 17.0. <h3>Results</h3> There were 65 JIA patients with age ranging 7-17 (mean age 15,8); 47(72%) girls and 18(28%) boys. The mean duration of the disease from the time of diagnosis till performing MRI for TMJ was 1,5 years (range 6 weeks-10 years). There were the following JIA types: seronegative polyarthritis 45(62%), seropositive polyarthritis 6%, olygoarthritis 12%, arthritis with entesitis 8%, undiferentiated 9% and 1,5% systemic and psoriatic arhtritis. 4 groups were separated after evaluating MRI findings: 1. with signs of acute arthritis (synovial enchancement, osseous oedema, synovial fluid) were 14(21%)patients;2. with structural damage of the joint ( erosions, flattening and deformation of the mandibular head)- 7(11%); 3. signs of acute arthritis with structural changes- 27(42%); 4. without any signs of damage- 17(26%). The mean count of active joints in 1. group were -5,6; 2. -1,3; 3. -4,8; 4.- 6,4. 32 patients with TMJ arthritis were evaluated and treated by ortodontist. For 29(91%) night splints were used, 15(47%)received i/a steroid injections, 14(44%) were treated with both- night splints and i/a injections. Remaining patients were treated with one of the methods: i/a injections- 1(3%), night splints 15(47%). <h3>Conclusions</h3> 1) Acute arthritis with structural joint damage was the most frequent finding of the MRI of TMJ in the JIA patients. 2) In cases of TMJ arthritis most often applied local therapy was night splints, less with i/a steroid injections. <h3>References</h3> Maria I. Argyropoulou, Persefoni N. Margariti, Aikaterini Karali. Temporomandibular joint involvement in juvenile idiopathic arthritis: clinical predictors of magnetic resonance imaging signs. Eur Radiol 2009;19:693-700. Ringold S, Torgerson TR, Egbert MA, Wallace CA. Intraarticular corticosteroid injections of the temporomandibular joint in juvenile idiopathic arthritis. J Rheumatol. 2008 Jun;35(6):1157-64 <h3>Disclosure of Interest</h3> None Declared